Clavulanate and Meropenem combination effective in dealing with TB

Bioanalytical

Clavulanate and Meropenem combination effective in dealing with TB

30 Mar, 2012

Published over 14 years ago. See the latest and most current information on Bioanalytical.

Biochemistry researchers have combined clavulanate and the antibiotic meropenem, finding that the pair offer an effective treatment for tuberculosis (TB).

John Blanchard, Ph.D., professor of Biochemistry at the Albert Einstein School of Medicine of Yeshiva University in New York City, said: "We've tested this combination against laboratory strains of Mtb, XDR and MDR strains from patients. In all cases, the combination doesn't just slows down growth — it kills the bacterium in laboratory tests."

The bacterium in TB has started to develop resistances to  current medication, which consists of isoniazid, pyrazinamide, rifampin, and ethambutol. Some strains of TB are resistant to more drugs, which makes this an increasingly pressing issue to deal with, for example, a physician in India reported a strain of TB that it 100 per cent drug resistant.

Combining clavulanate and meropenem kills MDR and XDR strains of Mtb, which contains beta-lactamase. This is what has been killing off antibiotics, and rendering many other drugs ineffective. The new study proved that clavulanate would stop the enzyme in TB microbes from attacking and destroying antibiotics.

Posted by Ben Evans 

Latest News

Explore Our Other Sites

Labmate Online
Severe asthma study discovers hidden clusters of long-term health conditions
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
DNV introduces new framework for measuring onboard carbon capture performance
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow